ID   MP2K6_HUMAN             Reviewed;         334 AA.
AC   P52564;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   15-MAR-2017, entry version 175.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 6;
DE            Short=MAP kinase kinase 6;
DE            Short=MAPKK 6;
DE            EC=2.7.12.2;
DE   AltName: Full=MAPK/ERK kinase 6;
DE            Short=MEK 6;
DE   AltName: Full=Stress-activated protein kinase kinase 3;
DE            Short=SAPK kinase 3;
DE            Short=SAPKK-3;
DE            Short=SAPKK3;
GN   Name=MAP2K6; Synonyms=MEK6, MKK6, PRKMK6, SKK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), MUTAGENESIS, AND FUNCTION.
RC   TISSUE=Skeletal muscle;
RX   PubMed=8622669; DOI=10.1128/MCB.16.3.1247;
RA   Raingeaud J., Whitmarsh A.J., Barrett T., Derijard B., Davis R.J.;
RT   "MKK3- and MKK6-regulated gene expression is mediated by the p38
RT   mitogen-activated protein kinase signal transduction pathway.";
RL   Mol. Cell. Biol. 16:1247-1255(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND ENZYME
RP   REGULATION.
RC   TISSUE=T-cell;
RX   PubMed=8626699; DOI=10.1074/jbc.271.19.11427;
RA   Stein B., Brady H., Yang M.X., Young D.B., Barbosa M.S.;
RT   "Cloning and characterization of MEK6, a novel member of the mitogen-
RT   activated protein kinase kinase cascade.";
RL   J. Biol. Chem. 271:11427-11433(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), TISSUE SPECIFICITY, AND
RP   MUTAGENESIS.
RC   TISSUE=Placenta;
RX   PubMed=8621675; DOI=10.1074/jbc.271.6.2886;
RA   Han J., Lee J.-D., Jiang Y., Li Z., Feng L., Ulevitch R.J.;
RT   "Characterization of the structure and function of a novel MAP kinase
RT   kinase (MKK6).";
RL   J. Biol. Chem. 271:2886-2891(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PHOSPHORYLATION, ENZYME
RP   REGULATION, AND FUNCTION.
RX   PubMed=8663074; DOI=10.1074/jbc.271.23.13675;
RA   Moriguchi T., Kuroyanagi N., Yamaguchi K., Gotoh Y., Irie K., Kano T.,
RA   Shirakabe K., Muro Y., Shibuya H., Matsumoto K., Nishida E.,
RA   Hagiwara M.;
RT   "A novel kinase cascade mediated by mitogen-activated protein kinase
RT   kinase 6 and MKK3.";
RL   J. Biol. Chem. 271:13675-13679(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8861944;
RA   Cuenda A., Alonso G., Morrice N., Jones M., Meier R., Cohen P.,
RA   Nebreda A.R.;
RT   "Purification and cDNA cloning of SAPKK3, the major activator of
RT   RK/p38 in stress- and cytokine-stimulated monocytes and epithelial
RT   cells.";
RL   EMBO J. 15:4156-4164(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION IN ACTIVATION OF MAPK13.
RX   PubMed=9218798; DOI=10.1093/emboj/16.12.3563;
RA   Goedert M., Cuenda A., Craxton M., Jakes R., Cohen P.;
RT   "Activation of the novel stress-activated protein kinase SAPK4 by
RT   cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison
RT   of its substrate specificity with that of other SAP kinases.";
RL   EMBO J. 16:3563-3571(1997).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9768359; DOI=10.1016/S0960-9822(98)70442-7;
RA   Ben-Levy R., Hooper S., Wilson R., Paterson H.F., Marshall C.J.;
RT   "Nuclear export of the stress-activated protein kinase p38 mediated by
RT   its substrate MAPKAP kinase-2.";
RL   Curr. Biol. 8:1049-1057(1998).
RN   [9]
RP   PHOSPHORYLATION BY MAP3K4.
RX   PubMed=9841871; DOI=10.1042/bj3360599;
RA   Chan-Hui P.Y., Weaver R.;
RT   "Human mitogen-activated protein kinase kinase kinase mediates the
RT   stress-induced activation of mitogen-activated protein kinase
RT   cascades.";
RL   Biochem. J. 336:599-609(1998).
RN   [10]
RP   PHOSPHORYLATION BY MAP3K2/MEKK2 AND MAP3K3/MEK3.
RX   PubMed=10347227; DOI=10.1074/jbc.274.23.16604;
RA   Deacon K., Blank J.L.;
RT   "MEK kinase 3 directly activates MKK6 and MKK7, specific activators of
RT   the p38 and c-Jun NH2-terminal kinases.";
RL   J. Biol. Chem. 274:16604-16610(1999).
RN   [11]
RP   INTERACTION WITH TAOK2, AND PHOSPHORYLATION BY TAOK2.
RX   PubMed=10497253; DOI=10.1074/jbc.274.40.28803;
RA   Chen Z., Hutchison M., Cobb M.H.;
RT   "Isolation of the protein kinase TAO2 and identification of its
RT   mitogen-activated protein kinase/extracellular signal-regulated kinase
RT   kinase binding domain.";
RL   J. Biol. Chem. 274:28803-28807(1999).
RN   [12]
RP   PHOSPHORYLATION BY MAP3K7/TAK1.
RX   PubMed=10094049; DOI=10.1038/18465;
RA   Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J., Cao Z.,
RA   Matsumoto K.;
RT   "The kinase TAK1 can activate the NIK-I kappaB as well as the MAP
RT   kinase cascade in the IL-1 signalling pathway.";
RL   Nature 398:252-256(1999).
RN   [13]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   PubMed=11104681; DOI=10.1042/bj3520739;
RA   Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.;
RT   "Susceptibility of mitogen-activated protein kinase kinase family
RT   members to proteolysis by anthrax lethal factor.";
RL   Biochem. J. 352:739-745(2000).
RN   [14]
RP   FUNCTION.
RX   PubMed=10961885;
RA   Visconti R., Gadina M., Chiariello M., Chen E.H., Stancato L.F.,
RA   Gutkind J.S., O'Shea J.J.;
RT   "Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4
RT   serine phosphorylation and transcriptional activity.";
RL   Blood 96:1844-1852(2000).
RN   [15]
RP   FUNCTION.
RX   PubMed=11727828; DOI=10.1515/BC.2001.178;
RA   Bode J.G., Ludwig S., Freitas C.A., Schaper F., Ruhl M., Melmed S.,
RA   Heinrich P.C., Haussinger D.;
RT   "The MKK6/p38 mitogen-activated protein kinase pathway is capable of
RT   inducing SOCS3 gene expression and inhibits IL-6-induced
RT   transcription.";
RL   Biol. Chem. 382:1447-1453(2001).
RN   [16]
RP   PHOSPHORYLATION BY MAP3K5/ASK1.
RX   PubMed=11689443; DOI=10.1093/emboj/20.21.6028;
RA   Morita K., Saitoh M., Tobiume K., Matsuura H., Enomoto S.,
RA   Nishitoh H., Ichijo H.;
RT   "Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5)
RT   in response to oxidative stress.";
RL   EMBO J. 20:6028-6036(2001).
RN   [17]
RP   PHOSPHORYLATION BY TAOK2.
RX   PubMed=11279118; DOI=10.1074/jbc.M100681200;
RA   Chen Z., Cobb M.H.;
RT   "Regulation of stress-responsive mitogen-activated protein (MAP)
RT   kinase pathways by TAO2.";
RL   J. Biol. Chem. 276:16070-16075(2001).
RN   [18]
RP   PHOSPHORYLATION BY MAP3K7/TAK1.
RX   PubMed=11460167; DOI=10.1038/35085597;
RA   Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J., Chen Z.J.;
RT   "TAK1 is a ubiquitin-dependent kinase of MKK and IKK.";
RL   Nature 412:346-351(2001).
RN   [19]
RP   INTERACTION WITH EIF2AK2, AND PHOSPHORYLATION.
RX   PubMed=15229216; DOI=10.1074/jbc.M406554200;
RA   Silva A.M., Whitmore M., Xu Z., Jiang Z., Li X., Williams B.R.;
RT   "Protein kinase R (PKR) interacts with and activates mitogen-activated
RT   protein kinase kinase 6 (MKK6) in response to double-stranded RNA
RT   stimulation.";
RL   J. Biol. Chem. 279:37670-37676(2004).
RN   [20]
RP   INTERACTION WITH DCTN1, AND MICROTUBULE-BINDING.
RX   PubMed=15375157; DOI=10.1074/jbc.C400333200;
RA   Cheung P.Y., Zhang Y., Long J., Lin S., Zhang M., Jiang Y., Wu Z.;
RT   "p150(Glued), Dynein, and microtubules are specifically required for
RT   activation of MKK3/6 and p38 MAPKs.";
RL   J. Biol. Chem. 279:45308-45311(2004).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF PAK6.
RX   PubMed=15550393; DOI=10.1074/jbc.M406701200;
RA   Kaur R., Liu X., Gjoerup O., Zhang A., Yuan X., Balk S.P.,
RA   Schneider M.C., Lu M.L.;
RT   "Activation of p21-activated kinase 6 by MAP kinase kinase 6 and p38
RT   MAP kinase.";
RL   J. Biol. Chem. 280:3323-3330(2005).
RN   [22]
RP   DOMAIN.
RX   PubMed=15866172; DOI=10.1016/j.molcel.2005.04.001;
RA   Takekawa M., Tatebayashi K., Saito H.;
RT   "Conserved docking site is essential for activation of mammalian MAP
RT   kinase kinases by specific MAP kinase kinase kinases.";
RL   Mol. Cell 18:295-306(2005).
RN   [23]
RP   ACETYLATION AT SER-207 AND THR-211, PHOSPHORYLATION AT SER-207 AND
RP   THR-211, INACTIVATION BY YERSINIA YOPJ, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=16728640; DOI=10.1126/science.1126867;
RA   Mukherjee S., Keitany G., Li Y., Wang Y., Ball H.L., Goldsmith E.J.,
RA   Orth K.;
RT   "Yersinia YopJ acetylates and inhibits kinase activation by blocking
RT   phosphorylation.";
RL   Science 312:1211-1214(2006).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   PHOSPHORYLATION BY MAP3K5/ASK1, ENZYME REGULATION, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RX   PubMed=20364819; DOI=10.1021/bi100010j;
RA   Sturchler E., Feurstein D., McDonald P., Duckett D.;
RT   "Mechanism of oxidative stress-induced ASK1-catalyzed MKK6
RT   phosphorylation.";
RL   Biochemistry 49:4094-4102(2010).
RN   [26]
RP   FUNCTION.
RX   PubMed=20869211; DOI=10.1016/j.jdermsci.2010.08.006;
RA   Kim M.Y., Choi T.Y., Kim J.H., Lee J.H., Kim J.G., Sohn K.C.,
RA   Yoon K.S., Kim C.D., Lee J.H., Yoon T.J.;
RT   "MKK6 increases the melanocyte dendricity through the regulation of
RT   Rho family GTPases.";
RL   J. Dermatol. Sci. 60:114-119(2010).
RN   [27]
RP   REVIEW ON ENZYME REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=9779990; DOI=10.1038/sj.onc.1202251;
RA   Dhanasekaran N., Premkumar Reddy E.;
RT   "Signaling by dual specificity kinases.";
RL   Oncogene 17:1447-1455(1998).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 45-332 OF MUTANT ASP-207 AND
RP   ASP-211, AND SUBUNIT.
RX   PubMed=19141286; DOI=10.1016/j.str.2008.11.007;
RA   Min X., Akella R., He H., Humphreys J.M., Tsutakawa S.E., Lee S.J.,
RA   Tainer J.A., Cobb M.H., Goldsmith E.J.;
RT   "The structure of the MAP2K MEK6 reveals an autoinhibitory dimer.";
RL   Structure 17:96-104(2009).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.26 ANGSTROMS) OF 47-334.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human mitogen-activated protein kinase kinase 6
RT   (mek6) activated mutant (s207d, t211d).";
RL   Submitted (JUL-2011) to the PDB data bank.
CC   -!- FUNCTION: Dual specificity protein kinase which acts as an
CC       essential component of the MAP kinase signal transduction pathway.
CC       With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of a
CC       threonine and a tyrosine residue in the MAP kinases p38 MAPK11,
CC       MAPK12, MAPK13 and MAPK14 and plays an important role in the
CC       regulation of cellular responses to cytokines and all kinds of
CC       stresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are both
CC       essential for the activation of MAPK11 and MAPK13 induced by
CC       environmental stress, whereas MAP2K6/MKK6 is the major MAPK11
CC       activator in response to TNF. MAP2K6/MKK6 also phosphorylates and
CC       activates PAK6. The p38 MAP kinase signal transduction pathway
CC       leads to direct activation of transcription factors. Nuclear
CC       targets of p38 MAP kinase include the transcription factors ATF2
CC       and ELK1. Within the p38 MAPK signal transduction pathway,
CC       MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14
CC       activation, and is therefore required for STAT4 activation and
CC       STAT4-regulated gene expression in response to IL-12 stimulation.
CC       The pathway is also crucial for IL-6-induced SOCS3 expression and
CC       down-regulation of IL-6-mediated gene induction; and for IFNG-
CC       dependent gene transcription. Has a role in osteoclast
CC       differentiation through NF-kappa-B transactivation by TNFSF11, and
CC       in endochondral ossification and since SOX9 is another likely
CC       downstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediates
CC       apoptotic cell death in thymocytes. Acts also as a regulator for
CC       melanocytes dendricity, through the modulation of Rho family
CC       GTPases. {ECO:0000269|PubMed:10961885,
CC       ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,
CC       ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,
CC       ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,
CC       ECO:0000269|PubMed:9218798}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activated by dual phosphorylation on Ser-207
CC       and Thr-211 in response to a variety of cellular stresses,
CC       including UV radiation, osmotic shock, hypoxia, inflammatory
CC       cytokines, interferon gamma (IFNG), and less often by growth
CC       factors. MAP2K6/MKK6 is activated by the majority of M3Ks, such as
CC       MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,
CC       MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.
CC       {ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,
CC       ECO:0000269|PubMed:8663074}.
CC   -!- SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its D
CC       domain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (By
CC       similarity). Interacts (via its DVD domain) with MAP3Ks activators
CC       like MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,
CC       MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (By
CC       similarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.
CC       {ECO:0000250, ECO:0000269|PubMed:10497253,
CC       ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,
CC       ECO:0000269|PubMed:19141286}.
CC   -!- INTERACTION:
CC       P24522:GADD45A; NbExp=2; IntAct=EBI-448135, EBI-448167;
CC       Q5S007:LRRK2; NbExp=4; IntAct=EBI-448135, EBI-5323863;
CC       Q9Y6R4:MAP3K4; NbExp=2; IntAct=EBI-448135, EBI-448104;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.
CC       Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=MKK6b;
CC         IsoId=P52564-1; Sequence=Displayed;
CC       Name=2; Synonyms=MKK6;
CC         IsoId=P52564-2; Sequence=VSP_004882;
CC   -!- TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletal
CC       muscle. Isoform 1 is expressed in skeletal muscle, heart, and in
CC       lesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.
CC   -!- INDUCTION: Strongly activated by UV, anisomycin, and osmotic shock
CC       but not by phorbol esters, NGF or EGF.
CC   -!- DOMAIN: The DVD domain (residues 311-334) contains a conserved
CC       docking site and is found in the mammalian MAP kinase kinases
CC       (MAP2Ks). The DVD sites bind to their specific upstream MAP kinase
CC       kinase kinases (MAP3Ks) and are essential for activation.
CC       {ECO:0000269|PubMed:15866172}.
CC   -!- DOMAIN: The D domain (residues 4-19) contains a conserved docking
CC       site and is required for the binding to MAPK substrates.
CC       {ECO:0000250}.
CC   -!- PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-
CC       211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,
CC       MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,
CC       MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.
CC   -!- PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ prevents
CC       phosphorylation and activation, thus blocking the MAPK signaling
CC       pathway. {ECO:0000269|PubMed:16728640}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U39657; AAC50389.1; -; mRNA.
DR   EMBL; U39656; AAC50388.1; -; mRNA.
DR   EMBL; U49732; AAB05035.1; -; mRNA.
DR   EMBL; U39065; AAB03705.1; -; mRNA.
DR   EMBL; U39064; AAB03708.1; -; mRNA.
DR   EMBL; D87905; BAA13496.1; -; mRNA.
DR   EMBL; X96757; CAA65532.1; -; mRNA.
DR   EMBL; BC012009; AAH12009.1; -; mRNA.
DR   CCDS; CCDS11686.1; -. [P52564-1]
DR   CCDS; CCDS82194.1; -. [P52564-2]
DR   PIR; S71631; S71631.
DR   RefSeq; NP_002749.2; NM_002758.3. [P52564-1]
DR   UniGene; Hs.463978; -.
DR   UniGene; Hs.49329; -.
DR   PDB; 2Y8O; X-ray; 1.95 A; B=4-17.
DR   PDB; 3ENM; X-ray; 2.35 A; A/B/C/D=45-332.
DR   PDB; 3FME; X-ray; 2.26 A; A=47-334.
DR   PDB; 3VN9; X-ray; 2.60 A; A=1-334.
DR   PDB; 5ETF; X-ray; 2.40 A; B=4-17.
DR   PDBsum; 2Y8O; -.
DR   PDBsum; 3ENM; -.
DR   PDBsum; 3FME; -.
DR   PDBsum; 3VN9; -.
DR   PDBsum; 5ETF; -.
DR   ProteinModelPortal; P52564; -.
DR   SMR; P52564; -.
DR   BioGrid; 111594; 26.
DR   DIP; DIP-31346N; -.
DR   IntAct; P52564; 12.
DR   MINT; MINT-3019559; -.
DR   STRING; 9606.ENSP00000468348; -.
DR   BindingDB; P52564; -.
DR   ChEMBL; CHEMBL2171; -.
DR   GuidetoPHARMACOLOGY; 2067; -.
DR   iPTMnet; P52564; -.
DR   PhosphoSitePlus; P52564; -.
DR   BioMuta; MAP2K6; -.
DR   DMDM; 1709088; -.
DR   EPD; P52564; -.
DR   MaxQB; P52564; -.
DR   PaxDb; P52564; -.
DR   PeptideAtlas; P52564; -.
DR   PRIDE; P52564; -.
DR   DNASU; 5608; -.
DR   Ensembl; ENST00000589647; ENSP00000467213; ENSG00000108984. [P52564-2]
DR   Ensembl; ENST00000590474; ENSP00000468348; ENSG00000108984. [P52564-1]
DR   Ensembl; ENST00000613873; ENSP00000477701; ENSG00000108984. [P52564-2]
DR   GeneID; 5608; -.
DR   KEGG; hsa:5608; -.
DR   UCSC; uc002jij.4; human. [P52564-1]
DR   CTD; 5608; -.
DR   DisGeNET; 5608; -.
DR   GeneCards; MAP2K6; -.
DR   HGNC; HGNC:6846; MAP2K6.
DR   HPA; CAB007744; -.
DR   HPA; HPA031134; -.
DR   MIM; 601254; gene.
DR   neXtProt; NX_P52564; -.
DR   OpenTargets; ENSG00000108984; -.
DR   PharmGKB; PA30591; -.
DR   eggNOG; KOG0984; Eukaryota.
DR   eggNOG; ENOG410XT3F; LUCA.
DR   GeneTree; ENSGT00760000119199; -.
DR   HOGENOM; HOG000234206; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; P52564; -.
DR   KO; K04433; -.
DR   OMA; EDFIATC; -.
DR   OrthoDB; EOG091G0A9H; -.
DR   PhylomeDB; P52564; -.
DR   BRENDA; 2.7.12.2; 2681.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-375170; CDO in myogenesis.
DR   Reactome; R-HSA-446652; Interleukin-1 signaling.
DR   Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; R-HSA-5210891; Uptake and function of anthrax toxins.
DR   Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation.
DR   SignaLink; P52564; -.
DR   SIGNOR; P52564; -.
DR   ChiTaRS; MAP2K6; human.
DR   EvolutionaryTrace; P52564; -.
DR   GeneWiki; MAP2K6; -.
DR   GenomeRNAi; 5608; -.
DR   PMAP-CutDB; P52564; -.
DR   PRO; PR:P52564; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000108984; -.
DR   CleanEx; HS_MAP2K6; -.
DR   ExpressionAtlas; P52564; baseline and differential.
DR   Genevisible; P52564; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004708; F:MAP kinase kinase activity; IBA:GO_Central.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:Reactome.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0060048; P:cardiac muscle contraction; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:ProtInc.
DR   GO; GO:0072709; P:cellular response to sorbitol; IEA:Ensembl.
DR   GO; GO:0006975; P:DNA damage induced protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0070423; P:nucleotide-binding oligomerization domain containing signaling pathway; TAS:Reactome.
DR   GO; GO:0022602; P:ovulation cycle process; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; IEA:Ensembl.
DR   GO; GO:0032308; P:positive regulation of prostaglandin secretion; IEA:Ensembl.
DR   GO; GO:0035897; P:proteolysis in other organism; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Complete proteome; Cytoplasm; Cytoskeleton; Kinase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Stress response; Transcription;
KW   Transcription regulation; Transferase; Tyrosine-protein kinase.
FT   CHAIN         1    334       Dual specificity mitogen-activated
FT                                protein kinase kinase 6.
FT                                /FTId=PRO_0000086386.
FT   DOMAIN       53    314       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      59     67       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        4     19       D domain. {ECO:0000250}.
FT   REGION      311    334       DVD domain.
FT   ACT_SITE    179    179       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      82     82       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE         14     15       Cleavage; by anthrax lethal factor.
FT   MOD_RES     207    207       O-acetylserine; by Yersinia yopJ;
FT                                alternate. {ECO:0000269|PubMed:16728640}.
FT   MOD_RES     207    207       Phosphoserine; by MAP3K; alternate.
FT                                {ECO:0000269|PubMed:16728640}.
FT   MOD_RES     211    211       O-acetylthreonine; by Yersinia yopJ;
FT                                alternate. {ECO:0000269|PubMed:16728640}.
FT   MOD_RES     211    211       Phosphothreonine; by MAP3K; alternate.
FT                                {ECO:0000269|PubMed:16728640}.
FT   VAR_SEQ       1     56       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8621675}.
FT                                /FTId=VSP_004882.
FT   MUTAGEN     207    207       S->A: Inactivation.
FT   MUTAGEN     207    207       S->E: Constitutive activation according
FT                                to PubMed:8622669, but not to
FT                                PubMed:8621675.
FT   MUTAGEN     211    211       T->A: Inactivation.
FT   MUTAGEN     211    211       T->E: Constitutive activation according
FT                                to PubMed:8622669, but not to
FT                                PubMed:8621675.
FT   CONFLICT    125    125       V -> M (in Ref. 3; AAB03705/AAB03708).
FT                                {ECO:0000305}.
FT   HELIX        50     52       {ECO:0000244|PDB:3FME}.
FT   STRAND       53     61       {ECO:0000244|PDB:3FME}.
FT   STRAND       63     72       {ECO:0000244|PDB:3FME}.
FT   TURN         73     76       {ECO:0000244|PDB:3FME}.
FT   STRAND       77     84       {ECO:0000244|PDB:3FME}.
FT   HELIX        90    104       {ECO:0000244|PDB:3FME}.
FT   TURN        110    112       {ECO:0000244|PDB:3VN9}.
FT   STRAND      115    120       {ECO:0000244|PDB:3FME}.
FT   STRAND      122    130       {ECO:0000244|PDB:3FME}.
FT   STRAND      133    135       {ECO:0000244|PDB:3FME}.
FT   HELIX       136    145       {ECO:0000244|PDB:3FME}.
FT   HELIX       152    172       {ECO:0000244|PDB:3FME}.
FT   HELIX       182    184       {ECO:0000244|PDB:3FME}.
FT   STRAND      185    187       {ECO:0000244|PDB:3ENM}.
FT   STRAND      193    195       {ECO:0000244|PDB:3FME}.
FT   HELIX       201    203       {ECO:0000244|PDB:3ENM}.
FT   HELIX       207    212       {ECO:0000244|PDB:3VN9}.
FT   HELIX       222    225       {ECO:0000244|PDB:3FME}.
FT   HELIX       236    252       {ECO:0000244|PDB:3FME}.
FT   HELIX       263    272       {ECO:0000244|PDB:3FME}.
FT   TURN        280    282       {ECO:0000244|PDB:3FME}.
FT   HELIX       285    294       {ECO:0000244|PDB:3FME}.
FT   HELIX       299    301       {ECO:0000244|PDB:3FME}.
FT   HELIX       305    308       {ECO:0000244|PDB:3FME}.
FT   HELIX       312    319       {ECO:0000244|PDB:3FME}.
FT   HELIX       324    332       {ECO:0000244|PDB:3FME}.
SQ   SEQUENCE   334 AA;  37492 MW;  4ECA8014522216AF CRC64;
     MSQSKGKKRN PGLKIPKEAF EQPQTSSTPP RDLDSKACIS IGNQNFEVKA DDLEPIMELG
     RGAYGVVEKM RHVPSGQIMA VKRIRATVNS QEQKRLLMDL DISMRTVDCP FTVTFYGALF
     REGDVWICME LMDTSLDKFY KQVIDKGQTI PEDILGKIAV SIVKALEHLH SKLSVIHRDV
     KPSNVLINAL GQVKMCDFGI SGYLVDSVAK TIDAGCKPYM APERINPELN QKGYSVKSDI
     WSLGITMIEL AILRFPYDSW GTPFQQLKQV VEEPSPQLPA DKFSAEFVDF TSQCLKKNSK
     ERPTYPELMQ HPFFTLHESK GTDVASFVKL ILGD
//
